Brief: Ryvu Therapeutics Updates Romacyclib Development Strategy
20/05/2026 16:04
May 20 (Reuters) - Ryvu Therapeutics SA RVU.WA: UPDATES ROMACYCLIB DEVELOPMENT STRATEGY TO FOCUS ON RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA PLANS TO ENROLL ABOUT 30 ADDITIONAL PATIENTS IN RIVER-81 STUDY TO SUPPORT POTENTIAL PARTNERING TRANSACTION RECENT DEVELOPMENT DECISIONS ARE NOT EXPECTED TO HAVE A MATERIAL NEGATIVE IMPACT ON 2026-2027 FINANCIAL OUTLOOK Source text: ID:nEM7pGw37a Further company coverage: RVU.WA (Reporting by Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ryvu Therapeutics SA
See all newsBrief: Ryvu Therapeutics Signs Grant Agreement For Panacea-Novo Project With The National Center For Research And Development
Brief: Ryvu Therapeutics Q2 Net Loss 13.1 Million Zlotys
Brief: Ryvu Therapeutics "Dualis" Project Recommended For 22.2 Mln Zloty Subsidy
Brief: Ryvu Therapeutics Launches Early Clinical Development Services Business For Biotech And Pharma In Europe
Brief: Ryvu Therapeutics Says Panacea-Novo Project Recommended For Funding Of 106.7 Mln Zlotys